<a href="https://laohu8.com/S/SVRA">Savara Inc</a>. Announces Publication of Phase 3 IMPALA-2 Trial Results in NEJM, Highlighting Efficacy of Molgramostim for Autoimmune PAP
Savara Inc. has announced that the results from its Phase 3 IMPALA-2 clinical trial will be published online in the New England Journal of Medicine (NEJM) on August 21, 2025. The trial focused on the use of inhaled molgramostim therapy in patients with autoimmune Pulmonary Alveolar Proteinosis (PAP), a rare respiratory disease. The study, characterized as the largest and longest Phase 3 clinical trial conducted in autoimmune PAP, demonstrated that 48 weeks of daily administration of molgramostim reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. The treatment was well tolerated with no notable safety concerns. The manuscript detailing the trial results will be available on the company's website following its publication in NEJM.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820194710) on August 20, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。